Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker assessment and molecular testing for prognostication in breast cancer

4 Dec 2015

Abstract excerpt

Current treatment of breast cancer incorporates clinical, pathological and molecular data. Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) define prognosis and identify tumours for targeted therapy, and remain the sole established single-molecule biomarkers defining the minimum breast cancer pathology data set. Ki67 remains one of the most promising yet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Gene expression and cancer classification
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26768030
DOI: 10.1111/his.12795

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker assessment and molecular testing for prognostication in breast cancerPMID 26768030Read ↗

Breast cancer biomarkers and molecular medicine.Semantic proximity Read ↗

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesSemantic proximity Read ↗

Advances in prognostic and predictive biomarkers for breast cancer: Integrating multigene assays, hormone receptors, and emerging circulating biomarkersSemantic proximity Read ↗

Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendationsSemantic proximity Read ↗

Comparing Molecular Biomarker Testing With Immunohistochemical Staining In Predicting Response To Neoadjuvant Therapy In Breast CancerSemantic proximity Read ↗

Molecular prognostic indicators for breast cancer.Semantic proximity Read ↗

Erratum to “Multi‐level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients” [MOLONC 8 (2014) 741–752]Semantic proximity Read ↗

Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer.Semantic proximity Read ↗

The Changing Role of Pathology in Breast Cancer Diagnosis and TreatmentSemantic proximity Read ↗

Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive reviewSemantic proximity Read ↗

Current and emerging breast cancer biomarkersSemantic proximity Read ↗

[Clinically relevant molecular pathological diagnostics in breast cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.